Financhill
Sell
31

IGMS Quote, Financials, Valuation and Earnings

Last price:
$1.28
Seasonality move :
28.2%
Day range:
$1.26 - $1.36
52-week range:
$0.92 - $22.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
28.79x
P/B ratio:
109.38x
Volume:
1.8M
Avg. volume:
908.9K
1-year change:
-89.15%
Market cap:
$76.3M
Revenue:
$2.7M
EPS (TTM):
-$3.27

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
IGMS
IGM Biosciences
$3.2M -$0.45 -100% -45.57% $1.12
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
OGEN
Oragenics
-- -- -- -- $1.00
SAGE
Sage Therapeutics
$16.7M -$0.94 95.69% -44.71% $8.73
SUPN
Supernus Pharmaceuticals
$154.1M $0.47 -8.33% 38.89% $39.00
TOVX
Theriva Biologics
-- -$0.47 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
IGMS
IGM Biosciences
$1.27 $1.12 $76.3M -- $0.00 0% 28.79x
NBY
NovaBay Pharmaceuticals
$0.65 $0.85 $3.8M -- $0.00 0% 0.16x
OGEN
Oragenics
$1.42 $1.00 $1M -- $0.00 0% 0.45x
SAGE
Sage Therapeutics
$9.13 $8.73 $571.7M -- $0.00 0% 11.79x
SUPN
Supernus Pharmaceuticals
$33.52 $39.00 $1.9B 30.20x $0.00 0% 2.81x
TOVX
Theriva Biologics
$0.47 $7.00 $3.8M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
IGMS
IGM Biosciences
-- -0.883 -- 5.39x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
OGEN
Oragenics
-- 0.068 -- --
SAGE
Sage Therapeutics
-- 0.392 -- 8.73x
SUPN
Supernus Pharmaceuticals
-- 0.372 -- 2.16x
TOVX
Theriva Biologics
-- -3.388 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
IGMS
IGM Biosciences
-- -$32.9M -241.68% -241.68% -6590.58% -$32.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
SAGE
Sage Therapeutics
$13.4M -$66.9M -64.19% -64.19% -476.02% -$81.7M
SUPN
Supernus Pharmaceuticals
$134.1M -$2.6M 6.24% 6.24% -1.73% $30.3M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

IGM Biosciences vs. Competitors

  • Which has Higher Returns IGMS or NBY?

    NovaBay Pharmaceuticals has a net margin of -10599.6% compared to IGM Biosciences's net margin of -49.65%. IGM Biosciences's return on equity of -241.68% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    IGMS
    IGM Biosciences
    -- -$0.86 $698K
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About IGMS or NBY?

    IGM Biosciences has a consensus price target of $1.12, signalling downside risk potential of -11.54%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that NovaBay Pharmaceuticals has higher upside potential than IGM Biosciences, analysts believe NovaBay Pharmaceuticals is more attractive than IGM Biosciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    IGMS
    IGM Biosciences
    0 4 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is IGMS or NBY More Risky?

    IGM Biosciences has a beta of 0.484, which suggesting that the stock is 51.552% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock IGMS or NBY?

    IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IGMS or NBY?

    IGM Biosciences quarterly revenues are $499K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. IGM Biosciences's net income of -$52.9M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, IGM Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 28.79x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IGMS
    IGM Biosciences
    28.79x -- $499K -$52.9M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns IGMS or OGEN?

    Oragenics has a net margin of -10599.6% compared to IGM Biosciences's net margin of --. IGM Biosciences's return on equity of -241.68% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IGMS
    IGM Biosciences
    -- -$0.86 $698K
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About IGMS or OGEN?

    IGM Biosciences has a consensus price target of $1.12, signalling downside risk potential of -11.54%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than IGM Biosciences, analysts believe Oragenics is more attractive than IGM Biosciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    IGMS
    IGM Biosciences
    0 4 0
    OGEN
    Oragenics
    0 1 0
  • Is IGMS or OGEN More Risky?

    IGM Biosciences has a beta of 0.484, which suggesting that the stock is 51.552% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

  • Which is a Better Dividend Stock IGMS or OGEN?

    IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IGMS or OGEN?

    IGM Biosciences quarterly revenues are $499K, which are larger than Oragenics quarterly revenues of --. IGM Biosciences's net income of -$52.9M is lower than Oragenics's net income of -$2.2M. Notably, IGM Biosciences's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 28.79x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IGMS
    IGM Biosciences
    28.79x -- $499K -$52.9M
    OGEN
    Oragenics
    0.45x -- -- -$2.2M
  • Which has Higher Returns IGMS or SAGE?

    Sage Therapeutics has a net margin of -10599.6% compared to IGM Biosciences's net margin of -442.4%. IGM Biosciences's return on equity of -241.68% beat Sage Therapeutics's return on equity of -64.19%.

    Company Gross Margin Earnings Per Share Invested Capital
    IGMS
    IGM Biosciences
    -- -$0.86 $698K
    SAGE
    Sage Therapeutics
    95.34% -$1.01 $409.8M
  • What do Analysts Say About IGMS or SAGE?

    IGM Biosciences has a consensus price target of $1.12, signalling downside risk potential of -11.54%. On the other hand Sage Therapeutics has an analysts' consensus of $8.73 which suggests that it could fall by -4.4%. Given that IGM Biosciences has more downside risk than Sage Therapeutics, analysts believe Sage Therapeutics is more attractive than IGM Biosciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    IGMS
    IGM Biosciences
    0 4 0
    SAGE
    Sage Therapeutics
    0 15 0
  • Is IGMS or SAGE More Risky?

    IGM Biosciences has a beta of 0.484, which suggesting that the stock is 51.552% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.557%.

  • Which is a Better Dividend Stock IGMS or SAGE?

    IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IGMS or SAGE?

    IGM Biosciences quarterly revenues are $499K, which are smaller than Sage Therapeutics quarterly revenues of $14.1M. IGM Biosciences's net income of -$52.9M is higher than Sage Therapeutics's net income of -$62.2M. Notably, IGM Biosciences's price-to-earnings ratio is -- while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 28.79x versus 11.79x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IGMS
    IGM Biosciences
    28.79x -- $499K -$52.9M
    SAGE
    Sage Therapeutics
    11.79x -- $14.1M -$62.2M
  • Which has Higher Returns IGMS or SUPN?

    Supernus Pharmaceuticals has a net margin of -10599.6% compared to IGM Biosciences's net margin of -7.89%. IGM Biosciences's return on equity of -241.68% beat Supernus Pharmaceuticals's return on equity of 6.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    IGMS
    IGM Biosciences
    -- -$0.86 $698K
    SUPN
    Supernus Pharmaceuticals
    89.48% -$0.21 $1B
  • What do Analysts Say About IGMS or SUPN?

    IGM Biosciences has a consensus price target of $1.12, signalling downside risk potential of -11.54%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $39.00 which suggests that it could grow by 16.35%. Given that Supernus Pharmaceuticals has higher upside potential than IGM Biosciences, analysts believe Supernus Pharmaceuticals is more attractive than IGM Biosciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    IGMS
    IGM Biosciences
    0 4 0
    SUPN
    Supernus Pharmaceuticals
    2 3 0
  • Is IGMS or SUPN More Risky?

    IGM Biosciences has a beta of 0.484, which suggesting that the stock is 51.552% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.700, suggesting its less volatile than the S&P 500 by 30.01%.

  • Which is a Better Dividend Stock IGMS or SUPN?

    IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IGMS or SUPN?

    IGM Biosciences quarterly revenues are $499K, which are smaller than Supernus Pharmaceuticals quarterly revenues of $149.8M. IGM Biosciences's net income of -$52.9M is lower than Supernus Pharmaceuticals's net income of -$11.8M. Notably, IGM Biosciences's price-to-earnings ratio is -- while Supernus Pharmaceuticals's PE ratio is 30.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 28.79x versus 2.81x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IGMS
    IGM Biosciences
    28.79x -- $499K -$52.9M
    SUPN
    Supernus Pharmaceuticals
    2.81x 30.20x $149.8M -$11.8M
  • Which has Higher Returns IGMS or TOVX?

    Theriva Biologics has a net margin of -10599.6% compared to IGM Biosciences's net margin of --. IGM Biosciences's return on equity of -241.68% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IGMS
    IGM Biosciences
    -- -$0.86 $698K
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About IGMS or TOVX?

    IGM Biosciences has a consensus price target of $1.12, signalling downside risk potential of -11.54%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than IGM Biosciences, analysts believe Theriva Biologics is more attractive than IGM Biosciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    IGMS
    IGM Biosciences
    0 4 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is IGMS or TOVX More Risky?

    IGM Biosciences has a beta of 0.484, which suggesting that the stock is 51.552% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock IGMS or TOVX?

    IGM Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGM Biosciences pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IGMS or TOVX?

    IGM Biosciences quarterly revenues are $499K, which are larger than Theriva Biologics quarterly revenues of --. IGM Biosciences's net income of -$52.9M is lower than Theriva Biologics's net income of -$4.3M. Notably, IGM Biosciences's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGM Biosciences is 28.79x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IGMS
    IGM Biosciences
    28.79x -- $499K -$52.9M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will GoodRX Stock Bounce Back?
Will GoodRX Stock Bounce Back?

GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…

Will FCX Benefit From Tariffs?
Will FCX Benefit From Tariffs?

Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…

Can Levi Stock Double?
Can Levi Stock Double?

Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…

Stock Ideas

Buy
70
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
82
SBET alert for Jul 17

SharpLink Gaming [SBET] is down 2.6% over the past day.

Buy
89
EXOD alert for Jul 17

Exodus Movement [EXOD] is down 4.14% over the past day.

Buy
60
U alert for Jul 17

Unity Software [U] is up 7.51% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock